[Recent advances in Saccharomyces boulardii research].
This review summarizes the probiotic mechanisms of action of Saccharomyces boulardii (S. boulardii) against inflammatory and non-inflammatory diarrheal conditions. S. boulardii is distributed in lyophilized form in many countries and used for the prevention of diarrhea in children and adults, including Clostridium difficile (C. difficile) associated infection. The main mechanisms of action of S. boulardii include inhibition of activities of bacterial pathogenic products, trophic effects on the intestinal mucosa, as well as modification of host signaling pathways involved in inflammatory and non-inflammatory intestinal diseases. S. boulardii inhibits production of pro-inflammatory cytokines by inhibiting main regulators of inflammation, including nuclear factor κB (NF-κB), and mitogen-activated protein kinases (MAP kinases), ERK1/2 and p38, but stimulates production of anti-inflammatory molecules such as peroxisome proliferator-activated receptor-gamma (PPAR-γ). Moreover, S. boulardii suppresses bacterial infection by inhibiting adhesion and/or overgrowth of bacteria, produces a serine protease that cleaves C. difficile toxin A, and stimulates antibody production against this toxin. Furthermore, S. boulardii may interfere with pathogenesis of Inflammatory Bowel Disease (IBD) by acting on T cells and acts in diarrheal conditions by improving the fecal biostructure in patients with diarrhea. These diverse mechanisms exerted by S. boulardii provide molecular clues for its effectiveness in diarrheal diseases and intestinal inflammatory conditions with an inflammatory component.
Im
E
E
Section of Inflammatory Bowel Disease and Inflammatory Bowel Disease Center, Division of Digestive Diseases, David Geffen School of Medicine, University of California-Los Angeles, CA 90095, United States.
Pothoulakis
C
C
D002448:Cell Adhesion / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D003967:Diarrhea / Q000178:diet therapy / Q000382:microbiology / Q000517:prevention & control*; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects; D016328:NF-kappa B / Q000187:drug effects; D047495:PPAR gamma / Q000096:biosynthesis; D019936:Probiotics / Q000627:therapeutic use*; D012440:Saccharomyces; D057057:Serine Proteases / Q000187:drug effects
D016207:Cytokines; D016328:NF-kappa B; D047495:PPAR gamma; D020928:Mitogen-Activated Protein Kinases; D057057:Serine Proteases